Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy CASI Pharmaceuticals stock
Learn how to easily invest in CASI Pharmaceuticals stock.
CASI Pharmaceuticals Inc is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 176 staff and has a trailing 12-month revenue of around $34.9 million.
How to buy shares in CASI Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CASI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
CASI Pharmaceuticals stock price (NASDAQ: CASI)Use our graph to track the performance of CASI stocks over time.
CASI Pharmaceuticals shares at a glance
|Latest market close||$2.68|
|52-week range||$2.24 - $12.70|
|50-day moving average||$3.35|
|200-day moving average||$5.45|
|Wall St. target price||$22.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.26|
Buy CASI Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CASI Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CASI Pharmaceuticals price performance over time
|1 week (2022-09-23)||2.29%|
|1 month (2022-09-01)||-29.10%|
|3 months (2022-07-01)||-7.27%|
|6 months (2022-03-31)||230.99%|
|1 year (2021-09-30)||125.21%|
|2 years (2020-10-01)||71.79%|
|3 years (2019-10-01)||3.29|
|5 years (2017-09-29)||51.41%|
CASI Pharmaceuticals financials
|Revenue TTM||$34.9 million|
|Gross profit TTM||$17.6 million|
|Return on assets TTM||-15.8%|
|Return on equity TTM||-30.23%|
|Market capitalisation||$35.6 million|
TTM: trailing 12 months
CASI Pharmaceuticals share dividends
We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.
Have CASI Pharmaceuticals's shares ever split?
CASI Pharmaceuticals's shares were split on a 1:10 basis on 1 June 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.
CASI Pharmaceuticals share price volatility
Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $2.24 up to $12.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.4435. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).
CASI Pharmaceuticals overview
CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co.
CASI Pharmaceuticals in the news
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA
Frequently asked questionsWhat percentage of CASI Pharmaceuticals is owned by insiders or institutions?
Currently 32.693% of CASI Pharmaceuticals shares are held by insiders and 16.294% by institutions. How many people work for CASI Pharmaceuticals?
Latest data suggests 176 work at CASI Pharmaceuticals. When does the fiscal year end for CASI Pharmaceuticals?
CASI Pharmaceuticals's fiscal year ends in December. Where is CASI Pharmaceuticals based?
CASI Pharmaceuticals's address is: 9620 Medical Center Drive, Rockville, MD, United States, 20850 What is CASI Pharmaceuticals's ISIN number?
CASI Pharmaceuticals's international securities identification number is: US14757U2087 What is CASI Pharmaceuticals's CUSIP number?
CASI Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14757U109
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert